Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL.

Mol Ther. 2010 Feb;18(2):435-41. doi: 10.1038/mt.2009.228.

2.

Rexin-G, a targeted genetic medicine for cancer.

Gordon EM, Hall FL.

Expert Opin Biol Ther. 2010 May;10(5):819-32. doi: 10.1517/14712598.2010.481666. Review.

PMID:
20384524
3.

Technology evaluation: Rexin-G, Epeius Biotechnologies.

Morse M.

Curr Opin Mol Ther. 2005 Apr;7(2):164-9. Review.

PMID:
15844625
4.

Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2).

André T, Noirclerc M, Hammel P, Meckenstock R, Landi B, Cattan S, Selle F, Codoul JF, Guerrier-Parmentier B, Mokhtar R, Louvet C; GERCOR..

Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):645-50. Review.

PMID:
15646530

Supplemental Content

Support Center